Literature DB >> 3051156

Clinical aspects of monosodium urate monohydrate crystal deposition disease (gout).

M A Becker1.   

Abstract

Gout is a clinical syndrome with a limited range of manifestations arising as a result of the deposition of crystals of monosodium urate, the final product of purine metabolism in humans. Hyperuricemia is a common chemical aberration that is most often mild and remains asymptomatic. Thus, hyperuricemia should be distinguished from gout, even though urate supersaturation is necessary for the expression of gout. Uric acid overproduction and diminished renal uric acid excretion are the major mechanisms resulting in hyperuricemia, and an understanding of the basis of hyperuricemia in individual gout patients is an important step in determining appropriate treatment and in identifying underlying disorders, offending drugs and toxins, and inherited enzyme defects, all of which can result in hyperuricemia and gout. A scheme is presented for the evaluation of patients with new-onset gout, along with a discussion of the relationships between gout/hyperuricemia and a variety of metabolic disorders that are unusually prevalent in gouty populations.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3051156

Source DB:  PubMed          Journal:  Rheum Dis Clin North Am        ISSN: 0889-857X            Impact factor:   2.670


  7 in total

1.  Inappropriate prescription of allopurinol and febuxostat and risk of adverse events in the elderly: results from the REPOSI registry.

Authors:  L Pasina; A L Brucato; C D Djade; P Di Corato; S Ghidoni; M Tettamanti; C Franchi; F Salerno; S Corrao; A Marengoni; M Marcucci; P M Mannucci; A Nobili
Journal:  Eur J Clin Pharmacol       Date:  2014-09-18       Impact factor: 2.953

Review 2.  Drug-induced rheumatic syndromes. Diagnosis, clinical features and management.

Authors:  M G Cohen; M V Prowse
Journal:  Med Toxicol Adverse Drug Exp       Date:  1989 May-Jun

3.  Theobromine inhibits uric acid crystallization. A potential application in the treatment of uric acid nephrolithiasis.

Authors:  Felix Grases; Adrian Rodriguez; Antonia Costa-Bauza
Journal:  PLoS One       Date:  2014-10-21       Impact factor: 3.240

4.  Seasonal variations of urate in a Swedish adult population.

Authors:  Axel Åkerblom; Johanna Helmersson-Karlqvist; Tomas Weitoft; Anders Larsson
Journal:  Clin Rheumatol       Date:  2017-03-10       Impact factor: 2.980

5.  Do etoricoxib and indometacin have similar effects and safety for gouty arthritis? A meta-analysis of randomized controlled trials.

Authors:  Tzu-Min Lin; Jia-En Chi; Chi-Ching Chang; Yi-No Kang
Journal:  J Pain Res       Date:  2018-12-19       Impact factor: 3.133

6.  Febuxostat in the management of hyperuricemia and chronic gout: a review.

Authors:  Miao Hu; Brian Tomlinson
Journal:  Ther Clin Risk Manag       Date:  2008-12       Impact factor: 2.423

Review 7.  Gout in the elderly. Clinical presentation and treatment.

Authors:  A G Fam
Journal:  Drugs Aging       Date:  1998-09       Impact factor: 4.271

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.